Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Multiple sclerosis: Fingolimod failure in progressive MS INFORMS future trials.

Literature DB >> 27020561

Multiple sclerosis: Fingolimod failure in progressive MS INFORMS future trials.

Andrew L Smith¹, Jeffrey A Cohen¹.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2016 PMID： 27020561 DOI： 10.1038/nrneurol.2016.37

Source DB: PubMed Journal: Nat Rev Neurol ISSN： 1759-4758 Impact factor: 42.937

× No keyword cloud information.

9 in total

1. Oral fingolimod (FTY720) for relapsing multiple sclerosis.

Authors: Ludwig Kappos; Jack Antel; Giancarlo Comi; Xavier Montalban; Paul O'Connor; Chris H Polman; Tomas Haas; Alexander A Korn; Goeril Karlsson; Ernst W Radue
Journal: N Engl J Med Date: 2006-09-14 Impact factor: 91.245

2. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

Authors: Peter A Calabresi; Ernst-Wilhelm Radue; Douglas Goodin; Douglas Jeffery; Kottil W Rammohan; Anthony T Reder; Timothy Vollmer; Mark A Agius; Ludwig Kappos; Tracy Stites; Bingbing Li; Linda Cappiello; Philipp von Rosenstiel; Fred D Lublin
Journal: Lancet Neurol Date: 2014-03-28 Impact factor: 44.182

3. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.

Authors: Jerry S Wolinsky; Ponnada A Narayana; Paul O'Connor; Patricia K Coyle; Corey Ford; Kenneth Johnson; Aaron Miller; Lillian Pardo; Shaul Kadosh; David Ladkani
Journal: Ann Neurol Date: 2007-01 Impact factor: 10.422

Review 4. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.

Authors: Daniel Ontaneda; Robert J Fox; Jeremy Chataway
Journal: Lancet Neurol Date: 2015-02 Impact factor: 44.182

Review 5. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.

Authors: Jeffrey A Cohen; Jerold Chun
Journal: Ann Neurol Date: 2011-05 Impact factor: 10.422

6. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Authors: Jeffrey A Cohen; Frederik Barkhof; Giancarlo Comi; Hans-Peter Hartung; Bhupendra O Khatri; Xavier Montalban; Jean Pelletier; Ruggero Capra; Paolo Gallo; Guillermo Izquierdo; Klaus Tiel-Wilck; Ana de Vera; James Jin; Tracy Stites; Stacy Wu; Shreeram Aradhye; Ludwig Kappos
Journal: N Engl J Med Date: 2010-01-20 Impact factor: 91.245

7. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

Authors: Kathleen Hawker; Paul O'Connor; Mark S Freedman; Peter A Calabresi; Jack Antel; Jack Simon; Stephen Hauser; Emmanuelle Waubant; Timothy Vollmer; Hillel Panitch; Jiameng Zhang; Peter Chin; Craig H Smith
Journal: Ann Neurol Date: 2009-10 Impact factor: 10.422

8. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.

Authors: Fred Lublin; David H Miller; Mark S Freedman; Bruce A C Cree; Jerry S Wolinsky; Howard Weiner; Catherine Lubetzki; Hans-Peter Hartung; Xavier Montalban; Bernard M J Uitdehaag; Martin Merschhemke; Bingbing Li; Norman Putzki; Fonda C Liu; Dieter A Häring; Ludwig Kappos
Journal: Lancet Date: 2016-01-28 Impact factor: 79.321

Review 9. Pathological mechanisms in progressive multiple sclerosis.

Authors: Don H Mahad; Bruce D Trapp; Hans Lassmann
Journal: Lancet Neurol Date: 2015-02 Impact factor: 44.182